Replies to post #224039 on Biotech Values

[semi_infinite]

EYPT - down 17% on $20M equity financing at 1.90. The good visibility on Yutiq uptake must be slow looking. Dexycu for cataract surgery is a bigger market.

http://www.biotuesdays.com/briefs/2019/3/28/eyepoint-pharma-prices-20-million-stock-offering